ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

GE HealthCare Advances PET/MR Capabilities with AIR Technologies

GE HealthCare is set to unveil SIGNA PET/MR AIRi, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting. The company will showcase the integration of its advanced AIR technologies with the SIGNA PET/MR AIR system, to enhance diagnostic precision, simplify treatment evaluation, while elevating patient comfort.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230623834778/en/

SIGNA™ PET/MR (Photo: Business Wire)

SIGNA™ PET/MR (Photo: Business Wire)

Recent FDA approvals of new PET radiotracers and therapeutic approaches for high-prevalence diseases, such as prostate cancer and Alzheimer's Disease, emphasize the need for reliable and comprehensive imaging solutions throughout the patient care journey. The unique AIR technologies from GE HealthCare incorporated into SIGNA PET/MR AIR address the evolving demands of these patient populations. These technologies include AIR Coils, which enhance and improve patient comfort, AIR Recon DL, which improves MR image quality and enables scan time reduction, and MotionFree Brainii, which mitigates motion-related PET image degradation.

Breakthroughs for Prostate Cancer Diagnosis and Treatment

Prostate cancer is the second most prevalent cancer in the world. Recently, prostate cancer care has undergone a transformation with the introduction of prostate-specific membrane antigen (PSMA)-targeted radiotracers for imaging diagnostics and theranostics, which combines diagnosis and therapy. The integration of PSMA-targeted PET radiotracers with GE HealthCare's high sensitivity PET and the anatomical precision of MRI in SIGNA PET/MR AIR holds the potential for precise diagnosis and staging/re-staging of prostate cancer. Additionally, it can aid in the selection of patients for subsequent PSMA-targeted radioligand therapyiii.

SIGNA PET/MR AIR delivers deep learning based MR image reconstruction with AIR Recon DL, helping to ensure both improved image quality and up to 50% in reduction of scan timeiv. GE HealthCare's AIR Coil technology effortlessly conforms to the shape of the human body, enhancing the quality of MR imaging while enhancing patient comfort. This technology offers a thinner, lighter solution, allowing for more accurate PET quantitation in contrast to conventional rigid RF coils.

Overcoming Barriers and Shaping the Future of Alzheimer's

With a staggering population of approximately 6.7 million Americans and 55 million worldwide affected by Alzheimer's Disease, GE HealthCare is committed to delivering products and solutions for accurate diagnosis, effective therapy planning, and continuous monitoring of the diseasev.

The recent approval of drugs with disease modifying potential require additional imaging of patients with both MR and PET. SIGNA PET/MR AIR offers the industry’s most sensitive Time-of-Flight (ToF) PET detector in a PET/MR, enabling clinicians to achieve the earliest possible diagnosis, gain insights into disease progression, and detect adverse effects in a single scan.

Addressing the challenge of patient movement during imaging exams, MotionFree Brain PET is a breakthrough solution on SIGNA PET/MR AIR that manages motion without external tracking devices. This helps to ensure consistent image quality even in challenging patients, potentially enabling faster and more accurate diagnosis, and minimizes the potential need for repeat scans.

"The SIGNA PET/MR AIR system continues our legacy of delivering innovative technologies that address a comprehensive range of clinical diseases,” said Jie Xue, President and CEO of MR at GE HealthCare. “Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer's Disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring. We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”

The introduction of the SIGNA PET/MR AIR system demonstrates GE HealthCare’s commitment to empowering healthcare professionals to deliver exceptional care and improve patient outcomes in the ever-evolving landscape of medical imaging.

_______________________

i Not CE Marked. Not available for sale in all regions. SIGNA PET/MR AIR is a premium configuration of SIGNA PET/MR

ii Not CE Marked. Not available for sale in all regions.

iii “Cancer.” World Health Organization. Feb 3, 2022. Accessed Jun 1, 2022. https://www.who.int/news-room/fact-sheets/detail/cancer

iv GE HealthCare Data on File

v https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.16
-0.51 (-0.22%)
AAPL  277.55
+0.58 (0.21%)
AMD  214.24
+8.11 (3.93%)
BAC  52.99
+0.51 (0.97%)
GOOG  320.28
-3.36 (-1.04%)
META  633.61
-2.61 (-0.41%)
MSFT  485.50
+8.51 (1.78%)
NVDA  180.26
+2.44 (1.37%)
ORCL  204.96
+7.93 (4.02%)
TSLA  426.58
+7.18 (1.71%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.